Ernexa Therapeutics Inc.
NASDAQ Global MarketTotal Valuation
Ernexa Therapeutics Inc. carries a market capitalization of 1.35M, placing it among publicly traded companies globally. Its enterprise value stands at -2.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.35M |
| Enterprise Value | -2.98M |
Share Statistics
Ernexa Therapeutics Inc. currently has 1.17M shares outstanding.
| Shares Outstanding | 1.17M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | -0.31 |
| P/OCF Ratio | -0.31 |
Enterprise Valuation
| EV / Sales | 6,160.35 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Ernexa Therapeutics Inc. maintains a current ratio of 2.89, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.89 |
| Quick Ratio | 2.68 |
| Debt / Equity | 5.67 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -687.76 |
| Return on Assets (ROA) | -145.97 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -93,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Ernexa Therapeutics Inc.'s stock has declined approximately -86.208% over the past 52 weeks. The 50-day moving average sits at 5.00, while the 200-day moving average is 13.23.
| Beta (5Y) | N/A |
| 52-Week Price Change | -86.208% |
| 50-Day Moving Average | 5.00 |
| 200-Day Moving Average | 13.23 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.85M, while operating income came in at -10.13M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -10.13M |
| Pretax Income | -11.48M |
| Net Income | -11.39M |
| EBITDA | -9.85M |
| EBIT | -10.13M |
| Earnings Per Share (EPS) | -25.72 |
Balance Sheet
Ernexa Therapeutics Inc. holds 9.18M in cash and equivalents against 389,000.00 in total debt, resulting in a net debt position of -9.18M. Total book value stands at 6.86M, with working capital of 6.54M providing operational flexibility.
| Cash & Cash Equivalents | 9.18M |
| Total Debt | 389,000.00 |
| Net Debt | -9.18M |
| Equity (Book Value) | 6.86M |
| Book Value Per Share | 5.88 |
| Working Capital | 6.54M |
Cash Flow
Ernexa Therapeutics Inc. produced -7.22M in operating cash flow over the past twelve months. After subtracting -39,000.00 in capital expenditures, free cash flow totaled -7.25M - equivalent to -16.39 per share.
| Operating Cash Flow | -7.22M |
| Capital Expenditures | -39,000.00 |
| Free Cash Flow | -7.25M |
| FCF Per Share | -16.39 |
Dividends & Yields
The company's payout ratio of 0.14 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 0.14 |
| Shareholder Yield | -249.95 |
| FCF Yield | -325.52 |
Stock Splits
Ernexa Therapeutics Inc.'s most recent stock split took place on May 4, 2026 with a 25:1 split ratio.
| Last Split Date | 5/4/2026 |
| Split Ratio | 25:1 |
Scores
Ernexa Therapeutics Inc. posts an Altman Z-Score of -34.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -34.83 |